Effectiveness of Nefopam for Thermoregulation During Surgery

NCT ID: NCT03122665

Last Updated: 2020-06-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

8 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-08-31

Study Completion Date

2006-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Nefopam may help blunt thermoregulatory defenses, thus facilitating induction of therapeutic hypothermia

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Hypothermia, whether therapeutically induced or unintentional, triggers thermoregulatory defenses including vasoconstriction and shivering. Nefopam, a non-opioid, nonsteroidal centrally acting analgesic, has an opioid-sparing effect and anti-shivering potency without sedation, making it an ideal candidate to counteract thermoregulatory shivering.

Since complete compartmental pharmacokinetics (PK) are lacking this prospective, randomized, double-blind study in 8 volunteers was set to investigate the PK of arterial nefopam samples with non-linear mixed effect modelling. A two compartment mammillary model independent of covariates was found to describe the data best and could be implemented to drive automated pumps, achieving and maintaining a desired plasma concentration.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypothermia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Volunteers given two doses of nefopam in a crossover protocol.
Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators
Blinded drug containers.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Nefopam low dose

Nefopam continuous intravenous infusion at 0.5 mg/ml for three hours.

Group Type ACTIVE_COMPARATOR

Nefopam Low dose

Intervention Type DRUG

Continuous intravenous infusion at 0.5 mg/ml for three hours.

Nefopam high dose

Nefopam continuous intravenous infusion at 1.0 mg/ml for three hours.

Group Type ACTIVE_COMPARATOR

Nefopam High dose

Intervention Type DRUG

Continuous intravenous infusion at 1.0 mg/ml for three hours.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nefopam Low dose

Continuous intravenous infusion at 0.5 mg/ml for three hours.

Intervention Type DRUG

Nefopam High dose

Continuous intravenous infusion at 1.0 mg/ml for three hours.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Low High

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Normal healthy volunteers ages 18-40

Exclusion Criteria

* history of alcohol or drug abuse
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Laboratoires Biocodex (Montrouge, France)

UNKNOWN

Sponsor Role collaborator

The Cleveland Clinic

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Anesthesiology, University of Bern

Bern, Freiburgstrasses, Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

180/03

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.